Use of systemic therapies in adults with atopic dermatitis: 12-month results from the European prospective observational study in patients eligible for systemic therapy for atopic dermatitis (EUROSTAD)
Background The European Prospective Observational Study in Patients Eligible for Systemic Therapy for Atopic Dermatitis (EUROSTAD) is an ongoing observational study aiming to describe characteristics of patients with atopic dermatitis (AD) treated with systemic therapy over time and the management o...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-07-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/09546634.2022.2038361 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832095402307878912 |
|---|---|
| author | Marjolein de Bruin-Weller Andrew E. Pink Silvia M. Ferrucci Annalisa Patrizi Ake Svensson Marie L. A. Schuttelaar Marie Tauber Marius Ardeleanu Shyamalie Jayawardena Moataz Daoud |
| author_facet | Marjolein de Bruin-Weller Andrew E. Pink Silvia M. Ferrucci Annalisa Patrizi Ake Svensson Marie L. A. Schuttelaar Marie Tauber Marius Ardeleanu Shyamalie Jayawardena Moataz Daoud |
| author_sort | Marjolein de Bruin-Weller |
| collection | DOAJ |
| description | Background The European Prospective Observational Study in Patients Eligible for Systemic Therapy for Atopic Dermatitis (EUROSTAD) is an ongoing observational study aiming to describe characteristics of patients with atopic dermatitis (AD) treated with systemic therapy over time and the management of their disease in a real-world setting.Methods Data from patients enrolled in EUROSTAD between March 2017 and April 2019 were analyzed for systemic therapy use and treatment change over 12 months.Results 288 patients reported taking systemic medications; 42.7% received cyclosporine, 35.3% dupilumab, 28.1% methotrexate, 25.4% oral corticosteroids, 6.8% azathioprine, 6.1% injectable corticosteroids, and 3.4% mycophenolate. The median duration of treatment was 1.1 months for oral systemic corticosteroids, 3.2 months for injectable corticosteroids, 4.8 months for cyclosporine, 7.3 months for methotrexate, and 14.9 months for dupilumab. The most frequent reasons for stopping treatment included lack of efficacy, patient decision, adverse events, and disease well controlled.Conclusion The 12-month interim EUROSTAD study analysis highlights the current trends and outcomes of systemic treatments for moderate-to-severe AD. Among all systemic treatments for AD, dupilumab was the least likely to be discontinued, whereas cyclosporine and corticosteroids, whilst effective, were primarily limited to episodic flare management consistent with treatment guidelines. |
| format | Article |
| id | doaj-art-94ac0c9eaf144d43bcac0c4ede538a57 |
| institution | Kabale University |
| issn | 0954-6634 1471-1753 |
| language | English |
| publishDate | 2022-07-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj-art-94ac0c9eaf144d43bcac0c4ede538a572025-02-05T19:02:55ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532022-07-013352565257010.1080/09546634.2022.2038361Use of systemic therapies in adults with atopic dermatitis: 12-month results from the European prospective observational study in patients eligible for systemic therapy for atopic dermatitis (EUROSTAD)Marjolein de Bruin-Weller0Andrew E. Pink1Silvia M. Ferrucci2Annalisa Patrizi3Ake Svensson4Marie L. A. Schuttelaar5Marie Tauber6Marius Ardeleanu7Shyamalie Jayawardena8Moataz Daoud9National Expertise Center of Atopic Dermatitis, Department of Dermatology and Allergology, University Medical Center, Utrecht, The NetherlandsSt. John’s Institute of Dermatology, Guy’s and St Thomas’ NHS Foundation Trust, London, UKDepartment of Dermatology, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, ItalyDepartment of Dermatology, IRCCS Policlinico di S. Orsola, Department of Experimental, Diagnostic, and Specialty Medicine, University of Bologna, Bologna, ItalySkåne University Hospital, Malmo, SwedenDermatology, University Medical Center Groningen, University of Groningen, Groningen, NetherlandsDermatology and Allergology Department, Toulouse University Hospital, and Institute for Infectious and Inflammatory Diseases, INSERM UMR1291 – CNRS UMR5051, Toulouse, FranceRegeneron Pharmaceuticals, Inc, Tarrytown, NY, USASanofi, Bridgewater, NJ, USASanofi Genzyme, Cambridge, MA, USABackground The European Prospective Observational Study in Patients Eligible for Systemic Therapy for Atopic Dermatitis (EUROSTAD) is an ongoing observational study aiming to describe characteristics of patients with atopic dermatitis (AD) treated with systemic therapy over time and the management of their disease in a real-world setting.Methods Data from patients enrolled in EUROSTAD between March 2017 and April 2019 were analyzed for systemic therapy use and treatment change over 12 months.Results 288 patients reported taking systemic medications; 42.7% received cyclosporine, 35.3% dupilumab, 28.1% methotrexate, 25.4% oral corticosteroids, 6.8% azathioprine, 6.1% injectable corticosteroids, and 3.4% mycophenolate. The median duration of treatment was 1.1 months for oral systemic corticosteroids, 3.2 months for injectable corticosteroids, 4.8 months for cyclosporine, 7.3 months for methotrexate, and 14.9 months for dupilumab. The most frequent reasons for stopping treatment included lack of efficacy, patient decision, adverse events, and disease well controlled.Conclusion The 12-month interim EUROSTAD study analysis highlights the current trends and outcomes of systemic treatments for moderate-to-severe AD. Among all systemic treatments for AD, dupilumab was the least likely to be discontinued, whereas cyclosporine and corticosteroids, whilst effective, were primarily limited to episodic flare management consistent with treatment guidelines.https://www.tandfonline.com/doi/10.1080/09546634.2022.2038361Real-world datadupilumabtreatment effectivenessatopic dermatitis |
| spellingShingle | Marjolein de Bruin-Weller Andrew E. Pink Silvia M. Ferrucci Annalisa Patrizi Ake Svensson Marie L. A. Schuttelaar Marie Tauber Marius Ardeleanu Shyamalie Jayawardena Moataz Daoud Use of systemic therapies in adults with atopic dermatitis: 12-month results from the European prospective observational study in patients eligible for systemic therapy for atopic dermatitis (EUROSTAD) Journal of Dermatological Treatment Real-world data dupilumab treatment effectiveness atopic dermatitis |
| title | Use of systemic therapies in adults with atopic dermatitis: 12-month results from the European prospective observational study in patients eligible for systemic therapy for atopic dermatitis (EUROSTAD) |
| title_full | Use of systemic therapies in adults with atopic dermatitis: 12-month results from the European prospective observational study in patients eligible for systemic therapy for atopic dermatitis (EUROSTAD) |
| title_fullStr | Use of systemic therapies in adults with atopic dermatitis: 12-month results from the European prospective observational study in patients eligible for systemic therapy for atopic dermatitis (EUROSTAD) |
| title_full_unstemmed | Use of systemic therapies in adults with atopic dermatitis: 12-month results from the European prospective observational study in patients eligible for systemic therapy for atopic dermatitis (EUROSTAD) |
| title_short | Use of systemic therapies in adults with atopic dermatitis: 12-month results from the European prospective observational study in patients eligible for systemic therapy for atopic dermatitis (EUROSTAD) |
| title_sort | use of systemic therapies in adults with atopic dermatitis 12 month results from the european prospective observational study in patients eligible for systemic therapy for atopic dermatitis eurostad |
| topic | Real-world data dupilumab treatment effectiveness atopic dermatitis |
| url | https://www.tandfonline.com/doi/10.1080/09546634.2022.2038361 |
| work_keys_str_mv | AT marjoleindebruinweller useofsystemictherapiesinadultswithatopicdermatitis12monthresultsfromtheeuropeanprospectiveobservationalstudyinpatientseligibleforsystemictherapyforatopicdermatitiseurostad AT andrewepink useofsystemictherapiesinadultswithatopicdermatitis12monthresultsfromtheeuropeanprospectiveobservationalstudyinpatientseligibleforsystemictherapyforatopicdermatitiseurostad AT silviamferrucci useofsystemictherapiesinadultswithatopicdermatitis12monthresultsfromtheeuropeanprospectiveobservationalstudyinpatientseligibleforsystemictherapyforatopicdermatitiseurostad AT annalisapatrizi useofsystemictherapiesinadultswithatopicdermatitis12monthresultsfromtheeuropeanprospectiveobservationalstudyinpatientseligibleforsystemictherapyforatopicdermatitiseurostad AT akesvensson useofsystemictherapiesinadultswithatopicdermatitis12monthresultsfromtheeuropeanprospectiveobservationalstudyinpatientseligibleforsystemictherapyforatopicdermatitiseurostad AT marielaschuttelaar useofsystemictherapiesinadultswithatopicdermatitis12monthresultsfromtheeuropeanprospectiveobservationalstudyinpatientseligibleforsystemictherapyforatopicdermatitiseurostad AT marietauber useofsystemictherapiesinadultswithatopicdermatitis12monthresultsfromtheeuropeanprospectiveobservationalstudyinpatientseligibleforsystemictherapyforatopicdermatitiseurostad AT mariusardeleanu useofsystemictherapiesinadultswithatopicdermatitis12monthresultsfromtheeuropeanprospectiveobservationalstudyinpatientseligibleforsystemictherapyforatopicdermatitiseurostad AT shyamaliejayawardena useofsystemictherapiesinadultswithatopicdermatitis12monthresultsfromtheeuropeanprospectiveobservationalstudyinpatientseligibleforsystemictherapyforatopicdermatitiseurostad AT moatazdaoud useofsystemictherapiesinadultswithatopicdermatitis12monthresultsfromtheeuropeanprospectiveobservationalstudyinpatientseligibleforsystemictherapyforatopicdermatitiseurostad |